Receptor Occupancy Measurement of Anti-Pd-1 Antibody Drugs in Support of Clinical Trials

Bioanalysis - United Kingdom
doi 10.4155/bio-2019-0090
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Future Science Ltd

Related search

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Comprehensive Molecular and Clinical Characterization of Asian Melanoma Patients Treated With Anti-Pd-1 Antibody

BMC Cancer
Cancer ResearchOncologyGenetics
2019English

Deficiencies in Anti-Acetylcholine Receptor Antibody Measurement in Myasthenia Gravis.

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
1991English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Clinical Implications of Anti-Thyroglobulin Antibody Measurement Before Surgery in Thyroid Cancer

Korean Journal of Internal Medicine
Internal Medicine
2018English

Genomics Drugs in Clinical Trials

Nature Reviews Drug Discovery
MedicineDrug DiscoveryPharmacology
2010English

Anti-Pd-1/Pd-L1 Antibody Versus Conventional Chemotherapy for Previously-Treated, Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials

Journal of Thoracic Disease
PulmonaryRespiratory Medicine
2017English

Occupancy of Agonist Drugs at the 5-Ht1a Receptor

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
2003English

Niraparib Activates Interferon Signaling and Potentiates Anti-Pd-1 Antibody Efficacy in Tumor Models

Scientific Reports
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy